According to IMARC Group’s latest report “Acute Myeloid Leukemia Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.’ offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios.
How big is the Acute Myeloid Leukemia Therapeutics Market?
The global acute myeloid leukemia therapeutics market size reached US$ 1,073.2 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 2,199.1 Million by 2028, exhibiting a growth rate (CAGR) of 12.4% during 2023-2028.
What is Acute Myeloid Leukemia Therapeutics?
Acute myeloid leukemia (AML) is a cancer of bone marrow and blood with excess immature white blood cells. It is characterized by breathlessness, fatigue, discoloration of the skin, high body temperatures, bleeding gums, weight loss, and nosebleeds. AML occurs when a bone marrow cell suddenly develops mutations in its deoxyribonucleic acid (DNA) or genetic material and its primary treatment includes chemotherapy, targeted drug, hormone, and radiation therapies, and stem cell transplant.
What are the growth prospects and trends in the acute myeloid leukemia therapeutics industry?
The increasing geriatric population and extended exposure to hazardous chemicals are some of the primary factors accelerating the market growth. Moreover, the surging prevalence of leukemia and the rising consumer awareness regarding the availability of AML therapeutics are propelling the market growth. Furthermore, key market players are investing heavily in research and development (R&D) activities to introduce improved monoclonal antibodies, immunotoxins, and multidrug-resistant modulators, offering enhanced results and efficacy, which is creating a positive outlook for the market.
This is further supported by the rapid approval of novel and innovative drugs and burgeoning government funding across the globe. Besides this, the improving healthcare infrastructure and rapid adoption of combination and targeted therapies are providing a considerable thrust to the market growth. Other factors, such as the rapidly expanding healthcare sector and significant technological advancements, are bolstering the market growth.
Request for a PDF Sample of this Report: https://www.imarcgroup.com/acute-myeloid-leukemia-therapeutics-market/requestsample
Who are the key players operating in the industry?
The report covers the major market players including:
- Abbvie Inc.
- Amgen Inc.
- Bristol-Myers Squibb Company
- Celgene
- Roche Holding AG
- Gilead Sciences Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A
- Takeda Pharmaceutical Company Limited.
Key Market Segmentation:
Breakup by Treatment Type:
- Cytarabine
- Anthracycline Drugs
- Alkylating Agents
- Anti-Metabolites
- Tyrosine Kinase Inhibitors
- Others
Breakup by Drug Type:
- Small Molecule Drugs
- Biopharmaceuticals
Breakup by Route of Administration:
- Oral
- Injectables
Breakup by Region:
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Others)
Ask Analyst for Customization: https://www.imarcgroup.com/request?type=report&id=3129&flag=E
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Media Contact:
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: sales@imarcgroup.com
Phone: +1-631-791-1145
Address: 134 N 4th St
City: Brooklyn
State: NY
Country: United States